The doctrine of equivalents allows a patentee to raise a claim of infringement even when each and every element of the patented invention is not identically present in the allegedly infringing product/process. The doctrine is aimed at preventing an infringer from gaining the benefit of a patented invention by making insubstantial changes. Disclosure-dedication doctrine is a bar to the doctrine of equivalents. Under the disclosure-dedication doctrine, when a patentee discloses subject matter but does not claim it, the patentee dedicates the unclaimed subject matter to the public and cannot recapture it through the doctrine of equivalents. The public can then practice the unclaimed subject matter without fear of infringement.Eagle Pharmaceuticals Inc. v. Slayback Pharma LLC, No. 2019-1924 (Fed. Cir. May 8, 2020) (“Eagle Pharm”) is the most recent Federal Circuit case involving this doctrine. In Eagle Pharm, the Federal Circuit considered whether a patentee can avoid dedication on the ground that the disclosure occurred in an embodiment distinct from the claimed invention. The court answered the question in the negative.
- Will SCOTUS Tell Bad Spaniels to Roll Over?
- DOJ Takes Key Step Toward Breaking Up Big Tech with Antitrust Complaint Against Google
- Federal Circuit Rejects St. Jude’s Challenge to Validity of Snyders’ Heart Valve Patent
- CAFC Affirms District Court Dismissal of Declaratory Judgment Under Doctrine of ‘Abstention’
- Federal Circuit Affirms PTAB Finding that Immunex Antibody Patent is Obvious
- American Innovators Express Support for Recent and Proposed Changes in Patent System
- This Week in Washington IP: Senate Commerce Committee to Grill Tech CEOs on Section 230, House Big Tech Antitrust Report and USPTO’s Quarterly TPAC Meeting
- Determining the Likelihood that an AI Patent Application Will Be Allowed at the USPTO
- Examining Samsung’s and LG’s LCD Patent Portfolios Following Decisions to Halt LCD Production
- Types of Subsequent Patent Applications in the United States (Part II)